Current Emergency Medical Service Vasoactive Use for the Management of Shock.

Q4 Medicine
Critical care explorations Pub Date : 2024-11-21 eCollection Date: 2024-12-01 DOI:10.1097/CCE.0000000000001177
Jason E Bloom, Vishal Goel, David Anderson, Susie Cartledge, Ziad Nehme, Jocasta Ball, Amminadab Eliakundu, William Chan, Derek P Chew, David M Kaye, Dion Stub
{"title":"Current Emergency Medical Service Vasoactive Use for the Management of Shock.","authors":"Jason E Bloom, Vishal Goel, David Anderson, Susie Cartledge, Ziad Nehme, Jocasta Ball, Amminadab Eliakundu, William Chan, Derek P Chew, David M Kaye, Dion Stub","doi":"10.1097/CCE.0000000000001177","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>We sought to describe the indications for vasoactive medication administration, hemodynamic treatment targets, and specific agents used by various international emergency medical service (EMS) providers.</p><p><strong>Design and setting: </strong>In March 2022, we sent an online survey comprising of 20 questions to Medical Directors of EMSs across Australia, the Asia Pacific region, and North America.</p><p><strong>Patients: </strong>A total of 108 EMS directors were emailed an invitation to participate.</p><p><strong>Interventions: </strong>None.</p><p><strong>Measurements and main results: </strong>Twenty-five EMS medical directors responded. Local site guidelines for vasoactive agent administration were available to 77.3% of providers. Epinephrine was commonly used as first-line vasoactive agent in 52% of questionnaire respondents, followed by norepinephrine (22%), dopamine (18%), and metaraminol (4%). Epinephrine was the most commonly used vasoactive agent across all forms of shock, with a higher proportion of utilization in cases of cardiogenic shock (58%) and patients suffering shock following cardiac arrest (56%).</p><p><strong>Conclusions: </strong>International EMS vasoactive use in the management of shock is heterogeneous. Future randomized controlled trials should aim to elucidate optimal prehospital treatment strategies for shock, including the initiation, choice of agent, and monitoring of vasoactive medication.</p>","PeriodicalId":93957,"journal":{"name":"Critical care explorations","volume":"6 12","pages":"e1177"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11584219/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical care explorations","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/CCE.0000000000001177","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: We sought to describe the indications for vasoactive medication administration, hemodynamic treatment targets, and specific agents used by various international emergency medical service (EMS) providers.

Design and setting: In March 2022, we sent an online survey comprising of 20 questions to Medical Directors of EMSs across Australia, the Asia Pacific region, and North America.

Patients: A total of 108 EMS directors were emailed an invitation to participate.

Interventions: None.

Measurements and main results: Twenty-five EMS medical directors responded. Local site guidelines for vasoactive agent administration were available to 77.3% of providers. Epinephrine was commonly used as first-line vasoactive agent in 52% of questionnaire respondents, followed by norepinephrine (22%), dopamine (18%), and metaraminol (4%). Epinephrine was the most commonly used vasoactive agent across all forms of shock, with a higher proportion of utilization in cases of cardiogenic shock (58%) and patients suffering shock following cardiac arrest (56%).

Conclusions: International EMS vasoactive use in the management of shock is heterogeneous. Future randomized controlled trials should aim to elucidate optimal prehospital treatment strategies for shock, including the initiation, choice of agent, and monitoring of vasoactive medication.

目前紧急医疗服务在处理休克时使用的血管活性药物。
目的:我们试图描述血管活性药物的给药适应症、血液动力学治疗目标以及国际急救医疗服务提供者使用的特定药物:我们试图描述血管活性药物的给药适应症、血液动力学治疗目标以及国际急救医疗服务(EMS)提供方使用的特定药物:2022 年 3 月,我们向澳大利亚、亚太地区和北美地区的急救医疗服务机构医务主任发送了一份包含 20 个问题的在线调查:我们通过电子邮件向 108 名急救中心主任发出了参与邀请:干预措施:无:二十五位急救医疗中心的医务主任做出了回应。77.3%的医疗服务提供者获得了当地的血管活性剂使用指南。在 52% 的问卷调查对象中,肾上腺素通常被用作一线血管活性剂,其次是去甲肾上腺素(22%)、多巴胺(18%)和美他明酚(4%)。肾上腺素是所有休克形式中最常用的血管活性药物,在心源性休克(58%)和心脏骤停后休克患者(56%)中的使用比例较高:结论:国际急救医疗系统在治疗休克时使用血管活性药物的情况不尽相同。未来的随机对照试验应旨在阐明最佳的院前休克治疗策略,包括血管活性药物的启动、药物选择和监测。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.70
自引率
0.00%
发文量
0
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信